Sinovac-QIV (quadrivalent influenza vaccine) / Sinovac - LARVOL DELTA

Influenza vaccines promote humoral and cellular immune responses: a randomized, double-blind, phase 3 trial. (PubMed, Nat Commun) - P3 | "Here, we report findings from a randomized, double-blind, active-controlled phase 3 clinical trial (NCT05431725) that includes 334 healthy adults aged 18-64 years and evaluates the humoral and cellular antiviral immune responses induced by two inactivated QIVs, Sinovac-QIV and Vaxigrip-Tetra™. Cellular immune responses using ELISPOT and supervised and unsupervised flow cytometry analyses show that both vaccines modulate the frequency of hemagglutinin-specific CD4+ and CD8+ T cell subsets, inducing distinct T cell response profiles. Although cellular analyses are evaluated in a subgroup of the cohort, the data indicate that both QIVs induce robust humoral and cellular immunity in adults, providing mechanistic insights into vaccine-induced protection."

Clinical • Journal • P3 data • Infectious Disease • Influenza • Respiratory Diseases • CD4 • CD8

Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women (clinicaltrials.gov) - P3 | N=150 | Not yet recruiting | Sponsor: Sinovac Biotech Co., Ltd

New P3 trial • Infectious Disease • Influenza • Respiratory Diseases

Immunogenicity and Safety of a Quadrivalent Influenza Vaccine in Population Aged 3 Years and Older in Chile and the Philippines: A Phase 3, Non-Inferiority, Double-Blind, Randomized Controlled Clinical Trial. (PubMed, Vaccines (Basel)) - "The immunogenicity of Sinovac QIV was non-inferior to that of the comparator QIV in these populations aged 3 years and older, and safety was comparable."

Clinical • Head-to-Head • Journal • P3 data • Infectious Disease • Influenza • Respiratory Diseases

Immunogenicity and Safety Study of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent (clinicaltrials.gov) - P3 | N=2202 | Completed | Sponsor: Sinovac Biotech Co., Ltd | Recruiting ➔ Completed

Trial completion • Infectious Disease • Influenza • Respiratory Diseases

Immunogenicity and Safety Study of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent (clinicaltrials.gov) - P3 | N=2161 | Recruiting | Sponsor: Sinovac Biotech Co., Ltd | N=1600 ➔ 2161 | Trial primary completion date: May 2023 ➔ Sep 2023

Enrollment change • Trial primary completion date • Infectious Disease • Influenza • Respiratory Diseases

Immunogenicity and Safety Study of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Chile (clinicaltrials.gov) - P3 | N=1600 | Recruiting | Sponsor: Sinovac Biotech (Chile) SpA | Not yet recruiting ➔ Recruiting | Trial completion date: Mar 2023 ➔ Jul 2023 | Trial primary completion date: Dec 2022 ➔ May 2023

Enrollment open • Trial completion date • Trial primary completion date • Infectious Disease • Respiratory Diseases